
Trump’s quest for Greenland could make Ozempic even more expensive
CNN
President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.
President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans. Trump has cranked up the pressure on Danish officials to sell the strategically important North American island, turning to his go-to tactic: Threatening tariffs. Massive ones. During a press conference on Monday, Trump vowed to slap “very high” tariffs on Denmark if it doesn’t sell the island to the United States. Greenland is a self-governing entity inside Denmark’s kingdom. (Trump also declined to rule out military force to seize Greenland.) Broadly speaking, high tariffs on Denmark might not cause significant trouble for American consumers because Denmark is not a huge trading partner with the United States. Danish goods account for less than half of 1% of total US imports. However, the United States did import around $5.7 billion worth of pharmaceutical products from Denmark in 2023, according to the most recent annual United Nations trade data compiled by Trading Economics. That figure is likely even higher for 2024 because Novo Nordisk, the Danish pharmaceutical giant, makes one of the hottest drugs on the market: Ozempic.

An initial reading of third-quarter gross domestic product showed the US economy expanded at an inflation-adjusted annualized rate of 4.3%, a far faster pace than the 3.8% recorded in the second quarter, according to Commerce Department data released Tuesday. That’s the fastest growth rate in two years.

Paramount has upped the ante in its hostile takeover bid for Warner Bros. Discovery, announcing Monday that Larry Ellison will personally guarantee the tens of billions of dollars he is putting up to bankroll the transaction. The Ellisons will also let shareholders peer into the finances of their family trust.











